Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
ANZ J Surg ; 91(1-2): 62-67, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32627365

RESUMO

BACKGROUND: Adrenocortical carcinoma is a rare but aggressive form of endocrine neoplasm that confers a poor prognosis. To date, the only Australian data published is from New South Wales. This paper describes our experience in Western Australia with a focus on surgical approach and outcomes. METHODS: A retrospective study of patients treated for adrenocortical carcinoma in Western Australia over 14 years was performed. RESULTS: Over the 14-year period, a total of 33 patients underwent surgery for adrenocortical carcinoma. Resection outcomes were superior in an open en bloc approach with an 85% R0 margin (P = 0.007). Local recurrence rates were lowest in an open en bloc approach (11%) compared to laparoscopic (75%). Multivariate analysis showed that an en bloc resection is highly correlated with an R0 resection (P < 0.05) and significantly associated with lower (odds ratio = 0.06) local recurrence (P = 0.009). Higher volume surgeons (>5 cases) had lower operative times and blood loss. Compliance with mitotane was significantly improved with close monitoring of levels. The European Network for the Study of Adrenal Tumours (ENSAT) stage at presentation was most predictive of long-term survival with 100% of stage I patients alive compared to 53% of stage II, 25% of stage III and 17% of stage IV patients at the end of the follow-up period. CONCLUSION: An open en bloc approach with a low threshold for multi-visceral resection performed by high volume surgeons have improved outcomes in local recurrence, operative times and blood loss.


Assuntos
Neoplasias do Córtex Suprarrenal , Carcinoma Adrenocortical , Neoplasias do Córtex Suprarrenal/epidemiologia , Neoplasias do Córtex Suprarrenal/cirurgia , Adrenalectomia , Carcinoma Adrenocortical/epidemiologia , Carcinoma Adrenocortical/cirurgia , Austrália , Humanos , Recidiva Local de Neoplasia/epidemiologia , New South Wales , Estudos Retrospectivos , Austrália Ocidental
2.
Environ Int ; 126: 430-442, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30836310

RESUMO

Waterborne and shellfish-borne enteric viruses associated with wastewater-polluted coastal waters (e.g. Norovirus, Hepatitis A/E viruses, Adenovirus) represent a major threat to human health. Improved understanding of the locations and periods of heightened risks can help target mitigation measures and improve public health. We developed a river-estuary-coast model to simulate virus dispersal, driven by point source discharges and river flows in combination with tidal forcing. Viral inputs were based on measured wastewater adenovirus concentrations and the model was implemented with or without viral die-off. We applied the model to the Conwy river (North Wales, UK), through the estuary, to the Irish Sea coast where bathing waters and shellfisheries are known to be prone to viral contamination. Using a suite of scenarios, we showed that river flow was the primary control of viral export to the coast. Since the Conwy catchment is short and steep, and the estuary is small and river-dominated, short-duration high intensity 'flash floods' were shown to transport viruses through the estuary and out to sea, despite dilution or die-off effects. Duplicating flow events (i.e., storm clustering) did not double the virus export since the virus re-entered the estuary on the flood tide. The tidal magnitude and timing of high water relative to peak river flow were also important drivers regulating viral dispersal. A worst-case event simulation (i.e., combining high river flows with high viral loading and high spring tide) resulted in increased concentrations of virus at nearby coasts, although the spatial spread was similar to the previous scenarios. Our results suggest that impact models for predicting and mitigating episodes of poor microbiological water quality may require careful representation of the intensity and timings of river flow when evaluating pathogen exposure risk.


Assuntos
Adenoviridae/isolamento & purificação , Estuários , Modelos Teóricos , Rios/microbiologia , Águas Residuárias/microbiologia , Monitoramento Ambiental/métodos , Inundações , Estações do Ano , País de Gales , Qualidade da Água
4.
BMC Cancer ; 13: 381, 2013 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-23937668

RESUMO

BACKGROUND: The kidneys are a principal dose-limiting organ in radiotherapy for upper abdominal cancers. The current understanding of kidney radiation dose response is rudimentary. More precise dose-volume response models that allow direct correlation of delivered radiation dose with spatio-temporal changes in kidney function may improve radiotherapy treatment planning for upper-abdominal tumours. METHODS/DESIGN: The Radiotherapy of Abdomen with Precise Renal Assessment with SPECT/CT Imaging (RAPRASI) is an observational clinical research study with participating sites at Sir Charles Gairdner Hospital (SCGH) in Perth, Australia and the Peter MacCallum Cancer Centre (PMCC) in Melbourne, Australia. Eligible patients are those with upper gastrointestinal cancer, without metastatic disease, undergoing conformal radiotherapy that will involve incidental radiation to one or both kidneys. For each patient, total kidney function is being assessed before commencement of radiotherapy treatment and then at 4, 12, 26, 52 and 78 weeks after the first radiotherapy fraction, using two procedures: a Glomerular Filtration Rate (GFR) measurement using the 51Cr-ethylenediamine tetra-acetic acid (EDTA) clearance; and a regional kidney perfusion measurement assessing renal uptake of 99mTc-dimercaptosuccinic acid (DMSA), imaged with a Single Photon Emission Computed Tomography / Computed Tomography (SPECT/CT) system. The CT component of the SPECT/CT provides the anatomical reference of the kidney's position. The data is intended to reveal changes in regional kidney function over the study period after the radiotherapy. These SPECT/CT scans, co-registered with the radiotherapy treatment plan, will provide spatial correlation between the radiation dose and regional renal function as assessed by SPECT/CT. From this correlation, renal response patterns will likely be identified with the purpose of developing a predictive model. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12609000322235.


Assuntos
Neoplasias Abdominais/radioterapia , Adenocarcinoma/radioterapia , Neoplasias Gastrointestinais/radioterapia , Rim/fisiopatologia , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Tomografia Computadorizada por Raios X/métodos , Neoplasias Abdominais/patologia , Adenocarcinoma/patologia , Seguimentos , Neoplasias Gastrointestinais/patologia , Taxa de Filtração Glomerular , Humanos , Rim/efeitos da radiação , Testes de Função Renal , Nova Zelândia , Prognóstico , Estudos Prospectivos , Radioterapia Conformacional
5.
Clin Nucl Med ; 38(1): 1-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23242037

RESUMO

PURPOSE OF THE REPORT: Pancreatic carcinoma is known to demonstrate molecular features of hypoxia. The aim of this prospective pilot study is to analyze the hypoxia agent fluoromisonidazole (FMISO) using PET/CT in pancreatic carcinoma and to compare FMISO activity with glucose metabolism reflected by FDG. PATIENTS AND METHODS: Ten patients with pancreatic carcinoma underwent FMISO and FDG PET scans. FMISO and FDG PET/CT scans were analyzed by 2 PET physicians. Regions of interest drawn on the FDG images were transposed to the FMISO images after study coregistration. The FDG SUVmax was used to quantify metabolic activity and FMISO SUVmax and tumor-to-background (muscle) ratio to quantify hypoxia. RESULTS: Seven patients were diagnosed with pancreatic adenocarcinoma. The remaining patients had a neuroendocrine tumor, poorly differentiated/sarcomatoid carcinoma, and mucinous neoplasm. Visual analysis demonstrated increased FMISO activity in 2 pancreatic adenocarcinomas. All patients, however, had increased FDG activity at the tumor site. Mean FDG SUVmax was 6 (range: 3.8 to 9.5) compared to 2.3 for FMISO (range: 1 to 3.4). The 2 positive studies on visual analysis of FMISO did not correspond to the largest tumors, the studies with the highest FMISO or FDG SUVmax. There was no significant correlation between FMISO and FDG SUVmax values. CONCLUSIONS: The hypoxia imaging agent, FMISO, demonstrates minimal activity in pancreatic tumors. If FMISO PET/CT is to be included in clinical trial protocols of hypoxia in pancreatic cancer, it would require correlation with other imaging modalities to localize the tumor and allow semiquantitative analysis.


Assuntos
Misonidazol/análogos & derivados , Imagem Multimodal , Neoplasias Pancreáticas/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios X , Adulto , Idoso , Hipóxia Celular , Feminino , Fluordesoxiglucose F18/farmacocinética , Humanos , Masculino , Pessoa de Meia-Idade , Misonidazol/farmacocinética , Neoplasias Pancreáticas/patologia
6.
Clin Cancer Res ; 16(8): 2409-17, 2010 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-20371686

RESUMO

PURPOSE: Existing prognostic systems for malignant pleural mesothelioma do not incorporate imaging information. We aimed to identify the contribution of quantitative fluorodeoxyglucose positron emission tomography (FDG-PET) analysis to other prognostic variables in this disease. EXPERIMENTAL DESIGN: Patients with malignant pleural mesothelioma underwent helical thoracoabdominal computed tomography and FDG-PET scans at baseline. Patients were treated as clinically indicated and followed for survival. FDG-PET variables derived included total glycolytic volume, a composite of tumor volume and glycolytic activity. RESULTS: Ninety-three patients were accrued from 2003 to 2006. Of 89 eligible assessable patients, 28 had undergone pleurodesis before enrolment. Seventeen patients remained alive at analysis; median survival is 15.4 months. On univariate analysis, significant prognostic factors were: total glycolytic volume on FDG-PET (P = 0.003), sarcomatoid histology (P < 0.0005), weight loss (P = 0.031), computed tomography stage (P = 0.015), and European Organization for Research and Treatment of Cancer good prognostic score (P = 0.049). In patients with epithelioid or biphasic histology, baseline total glycolytic volume remained predictive of survival in patients with (P = 0.01) or without (P = 0.018) previous pleurodesis. In multivariate analysis, no variable other than histology contributed to the model in patients with sarcomatoid histology; total glycolytic volume and weight loss contributed to the models in patients with nonsarcomatoid histology. computed tomography-assessed tumor-node-metastasis stage did not contribute to the model. A nomogram, which incorporates quantitative PET parameters and pleurodesis into prognostic information, is presented. CONCLUSIONS: Sarcomatoid histology remains the strongest prognostic factor. In patients with non sarcomatoid disease, volumetric FDG-PET parameters are more predictive of survival than tumor-node-metastasis staging, suggesting that tumor volume and glycolytic activity may be more important determinants of prognosis in malignant pleural mesothelioma than anatomic extent of disease.


Assuntos
Fluordesoxiglucose F18 , Mesotelioma/diagnóstico por imagem , Neoplasias Pleurais/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Feminino , Humanos , Masculino , Mesotelioma/patologia , Neoplasias Pleurais/patologia , Prognóstico , Taxa de Sobrevida , Tomografia Computadorizada por Raios X
7.
Eur J Nucl Med Mol Imaging ; 36(3): 347-53, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18931840

RESUMO

PURPOSE: Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans. METHODS: PET resulted in management plan changes in 74 patients with untreated low-grade NHL stages I to III. Patient outcomes to 12 months were documented. RESULTS: PET identified additional lesions in 50% of patients, led to a change in stage in 32%, and had a significant impact on management in 34%. Inferior progression-free survival was noted in patients with additional lesions detected by PET (p=0.001) and in the 28% of patients upstaged by PET to stage III or IV (p=0.024). In a subset of 16 patients undergoing both PET and gallium scans, PET was found to be superior. CONCLUSION: PET has a major role in the management of low-grade NHL in addition to its proven role in aggressive lymphoma.


Assuntos
Radioisótopos de Gálio , Linfoma não Hodgkin/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Intervalo Livre de Doença , Radioisótopos de Flúor , Fluordesoxiglucose F18 , Humanos , Linfoma não Hodgkin/patologia , Estadiamento de Neoplasias/métodos , Prognóstico , Estudos Prospectivos , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X
8.
Bioorg Med Chem Lett ; 18(21): 5717-21, 2008 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-18851911

RESUMO

Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilinopyrimidines. The observed range of cellular activities has been rationalised on the basis of physicochemical and structural characteristics.


Assuntos
Inibidores de Proteínas Quinases/farmacologia , Pirimidinas/farmacologia , Receptor EphB4/antagonistas & inibidores , Modelos Moleculares , Estrutura Molecular , Inibidores de Proteínas Quinases/química , Pirimidinas/química
12.
Cancer Res ; 67(3): 940-5, 2007 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-17283124

RESUMO

5-Fluorouracil (FU) has been widely used for more than four decades in the treatment of a range of common cancers. The fluorine-substituted uracil analogue is converted to several active metabolites but the mechanism of cytotoxicity has remained unclear. In a widely cited but unsubstantiated model, FU is thought to kill cells via the inhibition of thymidylate synthase and increased use of dUTP in place of TTP during DNA replication, with subsequent excision of high levels of uracil causing the fragmentation of newly synthesized DNA. Using gene-targeted cell lines defective in one or both of the two mammalian uracil-DNA glycosylase repair enzymes, we were able to test this model of FU cytotoxicity. Here, we show that incorporation of FU itself into DNA has been previously underestimated and is a predominant cause of cytotoxicity. FU readily becomes incorporated into the DNA of drug-treated cells, and accumulation of FU in the genome, rather than uracil excision, is correlated with FU cytotoxicity in mammalian cells. Furthermore, the Smug1, but not the Ung, uracil-DNA glycosylase excises FU from DNA and protects against cell killing. The data provides a clearer understanding of the action of FU, suggesting predictive biomarkers of drug response and a mechanism for acquired resistance in tumors.


Assuntos
Reparo do DNA , DNA/metabolismo , Fluoruracila/metabolismo , Fluoruracila/farmacologia , Uracila-DNA Glicosidase/metabolismo , Animais , Antimetabólitos Antineoplásicos/metabolismo , Antimetabólitos Antineoplásicos/farmacocinética , Antimetabólitos Antineoplásicos/farmacologia , Linhagem Celular , Dano ao DNA , Fibroblastos/efeitos dos fármacos , Fibroblastos/enzimologia , Fibroblastos/metabolismo , Fluoruracila/farmacocinética , Humanos , Camundongos , RNA Interferente Pequeno/genética , Uracila-DNA Glicosidase/biossíntese , Uracila-DNA Glicosidase/deficiência , Uracila-DNA Glicosidase/genética
13.
Clin Nucl Med ; 30(9): 617-8, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16100483

RESUMO

A patient with a history of colon carcinoma and computed tomography (CT) evidence suggestive of a liver metastasis underwent an F-18 FDG PET scan. The PET scan confirmed a metastasis in the left lobe of the liver. The study also demonstrated bilateral symmetric uptake involving the inferior subscapular regions. Correlation with the previous CT showed this to correspond to bilateral elastofibroma dorsi, which had been prospectively reported on the CT. Elastofibroma dorsi is a rare benign mass consisting of fibroelastic tissue and fat. It has been previously described on PET, CT, ultrasound, and magnetic resonance imaging (MRI). On CT, the masses are of soft tissue density, similar to adjacent musculature, and may contain linear areas of low density secondary to fat. On MRI, elastofibroma dorsi has been shown to have variable enhancement, which may reflect increased vascularity of the lesion. In this case, the masses demonstrated low-grade diffuse F-18 FDG uptake.


Assuntos
Dorso/diagnóstico por imagem , Fibroma/diagnóstico por imagem , Fibroma/metabolismo , Fluordesoxiglucose F18/farmacocinética , Neoplasias de Tecidos Moles/diagnóstico por imagem , Neoplasias de Tecidos Moles/metabolismo , Humanos , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética
14.
EMBO J ; 24(12): 2205-13, 2005 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-15902269

RESUMO

The most common genetic change in aerobic organisms is a C:G to T:A mutation. C --> T transitions can arise through spontaneous hydrolytic deamination of cytosine to give a miscoding uracil residue. This is also a frequent DNA lesion induced by oxidative damage, through exposure to agents such as ionizing radiation, or from endogenous sources that are implicated in the aetiology of degenerative diseases, ageing and cancer. The Ung and Smug1 enzymes excise uracil from DNA to effect repair in mammalian cells, and gene-targeted Ung(-/-) mice exhibit a moderate increase in genome-wide spontaneous mutagenesis. Here, we report that stable siRNA-mediated silencing of Smug1 in mouse embryo fibroblasts also generates a mutator phenotype. However, an additive 10-fold increase in spontaneous C:G to T:A transitions in cells deficient in both Smug1 and Ung demonstrates that these enzymes have distinct and nonredundant roles in suppressing C --> T mutability at non-CpG sites. Such cells are also hypersensitive to ionizing radiation, and reveal a role of Smug1 in the repair of lesions generated by oxidation of cytosine.


Assuntos
DNA Glicosilases/deficiência , Raios gama , Mutagênese/fisiologia , Mutação Puntual , Animais , Citosina/química , Citosina/metabolismo , DNA Glicosilases/genética , DNA Glicosilases/metabolismo , Camundongos , Mutagênese/genética , Interferência de RNA , RNA Interferente Pequeno , Tolerância a Radiação/genética , Tolerância a Radiação/fisiologia , Uracila-DNA Glicosidase
15.
Mol Cell Biol ; 24(15): 6719-27, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15254239

RESUMO

TREX1, originally designated DNase III, was isolated as a major nuclear DNA-specific 3'-->5' exonuclease that is widely distributed in both proliferating and nonproliferating mammalian tissues. The cognate cDNA shows homology to the editing subunit of the Escherichia coli replicative DNA polymerase III holoenzyme and encodes an exonuclease which was able to serve a DNA-editing function in vitro, promoting rejoining of a 3' mismatched residue in a reconstituted DNA base excision repair system. Here we report the generation of gene-targeted Trex1(-/-) mice. The null mice are viable and do not show the increase in spontaneous mutation frequency or cancer incidence that would be predicted if Trex1 served an obligatory role of editing mismatched 3' termini generated during DNA repair or DNA replication in vivo. Unexpectedly, Trex1(-/-) mice exhibit a dramatically reduced survival and develop inflammatory myocarditis leading to progressive, often dilated, cardiomyopathy and circulatory failure.


Assuntos
Exodesoxirribonucleases/fisiologia , Marcação de Genes , Miocardite/genética , Fosfoproteínas/fisiologia , Animais , Southern Blotting , Divisão Celular , Sobrevivência Celular , DNA/metabolismo , Reparo do DNA , DNA Complementar/metabolismo , Relação Dose-Resposta a Droga , Exodesoxirribonucleases/genética , Genótipo , Inflamação , Camundongos , Camundongos Transgênicos , Modelos Genéticos , Mutagênese , Mutação , Miocárdio/patologia , Fosfoproteínas/genética , Estrutura Terciária de Proteína , Timo/patologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA